Callerio Foundation

Literature of biological and pharmacological relevance
on ruthenium compounds

1. Thomson AJ., Williams RJP., Reslova S.
The chemistry of complexes related to cis-Pt(NH3)2Cl2. An anti-tumour drug.
In: Structure Bonding 11: 1-47, 1972, Berlin.

2. Cleare MJ., Hydes PC.
Anti-tumour properties of metal complexes.
11: 1-62, 1979. In: Metal Ions in Biological Systems. Eds: Marcel Dekker, New York.

3. Kelman AD., Clarke MJ., Edmonds SD., Peresie HJ.
Biological activity of ruthenium purine complexes.
J. Clin. Hematol. Oncol. 7: 1: 274-288, 1977.

4. Stern EW.
The search for new platinum antitumor agents: progress, problems and prospects.
In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, eds: M Nicolini. Boston 519-524, 1988.

5. Giraldi T, Sava G, Bertoli G, Mestroni G, Zassinovich G.
Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloro-platinum(II).
"Cancer Res", 37: 2662-2666 (1977).

6. Sava G, Giraldi T, Mestroni G, Zassinovich G.
Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma.
"Chem Biol Interactions", 45: 1-6 (1983).

7. Sava G, Zorzet S, Giraldi T, Mestroni G, Zassinovich G.
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms.

"Eur J Cancer Clin Oncol", 20: 841-847 (1984).

8. Clarke MJ., Galang RD., Rodriguez VM., Kumar R., Pell S., Bryan DM.
Chemical considerations in the design of ruthenium anticancer agents.
In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. EDS: M Nicolini, Boston, 582-601, 1988.

9. Clarke MJ., Buchbinder M.
Binding of pentammineruthenium(III) to double-helical and single-stranded DNA.
Inorganica Chimica Acta 27: L87-L88, 1978.

10. Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M.
The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes.
In: Metal Complexes in Cancer Chemotherapy. Ed: BK Keppler by Verlaggesellschaft, Weiheim. 157-185, 1993a.

11. Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M., Boccarelli A.
Water-soluble ruthenium(III)-dimethylsulfoxide complexes: chemical behaviour and pharmaceutical properties.
Metal Based Drugs 1: 1: 41-63, 1993b.

12. Sava G.
Ruthenium compounds in cancer therapy.
In: Metal Compounds in Cancer Therapy. Ed: Simon Fricker, by Chapman & Hall, London. 65-91, 1994.

13. Keppler BK., Berger MR., Heim ME.
New tumor-inhibiting metal complexes.
Cancer Treat. Rev. 17: 261-277, 1990.

14. Clarke MJ.
Ruthenium chemistry pertaining to the design of anticancer agents.
In: Progress in Clinical Biochemistry and Medicine, Vol: 10, Springer-Verlag Berlin, 25-39, 1989.

15. Keppler BK., Henn M., Juhl UM., Berger MR., Niebl R., Wagner FE.
New ruthenium complexes for the treatment of cancer.
In: Progress in Clinical Biochemistry and Medicine, vol 10, Springer-Verlag Berlin Heidelberg p. 41-69, 1989.

16. Sava G, Pacor S, Bregant F, Ceschia V, Mestroni G.
Metal complexes of ruthenium: antineoplastic properties and perspectives
"Anti-Cancer Drugs", 1: 99-108 (1990b).

17. Luft JH.
The fine structure of hyaline cartilage matrix following ruthenium red fixative and staining.
J. Cell Biol. 27:61a, 1965.

18. Engfeldt B, Hjertquist SO.
Studies on the epiphyseal growth zone.
Vierchow. Arch. [Cell Pathol.] 1: 222-229, 1968.

19. Hunziker EB., HeRuthenium Redmann W., Schenk RK.
Improved cartilage fixation by ruthenium hexammine trichloride (RHT). A prerequisite for morphometry in growth cartilage.
J. Ultrastruct. Res. 81: 1-12, 1982.

20. Hunziker EB., HeRuthenium Redmann W., Schenk RK.
Ruthenium hexammine trichloride (RHT)-metiated interaction between plasmalemmal components and pericellular matrix proteoglycans is responsible for the preservation of chondrocytic plasma membranes in situ during cartilage fixation
J. Histochem. Cytochem. 31: 6: 717-727, 1983.

21. Nuehring LP., Steffens WL., Rowland GN.
Comparison of the Ruthenium hexammine trichloride method to other methods of chemical fixation for preservation of avian physeal cartilage.
Histochem. Journal 23: 201-214, 1991.

22. Fletcher JM., Greenfield BF., Hardy CJ., et al.
Ruthenium Red.
J. Chem. Soc. 2000-2006, 1961.

23. Luft JH.
Electron microscopy of cell extraneous coats as revealed by ruthenium red staining.
J. Cell. Biol. 23: 54a, 1964.

24. Luft JH.
Fine structure of capillary and endocapillary layer as revealed by ruthenium red
Fed. Proc. 25: 1773-1783, 1966.

25. Handley PS., Hargreaves J., Harty DW.
Ruthenium red staining reveals surface fibrils and a layer external to the cell wall in Streptococcus salivarius HB and adhesion deficient mutants.
J. Gen. Microbiol. 134: 3165-3172, 1988.

26. Alroy J., Goyal V., Ucci AA., Klauber GT., Heaney JA., Choen SM.
Cell surface coat of human and rat bladder urothelium. I. Ruthenium Red studies in non-neoplastic and neoplastic cells
Virchows Arch. [Cell Pathol.] 42: 251-262, 1983.

27. Ghosh L., Nassauer J., Faiferman I., Ghosh BC.
Ultrastructural study of membrane glycocalyx in primary and metastatic human and rat mammary carcinoma.
J. Surg. Oncol. 17: 395-401, 1981.

28. Sugihara S., Yamamoto T., Tsuruta J., Tanaka J., Hiroaka T., Tashiro S., Miyauchi Y., Kambara T.
Enzyme-induced aggregation and disaggregation of tumor cells via the cell surface glycocalyx in association with deoxyribonucleic acid.
Acta Pathol. Japon. 41: 5: 327-335, 1991.

29. Deinum J., Wallin M., Jensen PW.
The binding of Ruthenium Red to tubulin.
Biochim. Biophys. Acta. 838: 197-205, 1985.

30. Moore CL.
Specific inhibition of mitochondrial Ca++ transport by ruthenium red
Biochem. Biophys. Res.

31. Ferrari R., di Lisa F., Raddino R., Visioli O.
The effects of ruthenium red on mitochondrial function during post-ischaemic reperfusion.
J. Mol. Cell. Cardiol. 14: 737-740, 1982.

32. Park Y., Bowles DK., Kehrer JP.
Protection against hypoxic injury in isolated- perfused rat heart by ruthenium red.
J. Pharmacol. Expl. Ther. 253: 2: 628-635, 1990.

33. Benzi RH., Lerch R.
Dissociation between contractile function and oxidative metabolism in postischemic myocardium. Attenuation by ruthenium red administered during reperfusion
Circulation Res. 71: 3: 567-576, 1992.

34. Missiaen L., De Smedt H., Droogmans G., Wuytack F., Raeymaekers L., Casteels R.
Ruthenium red and compound 48/80 inhibit the smooth-muscle plasma-membrane Ca2+ pump via interaction with associated polyphosphoinositides.
Biochem. Biophys. Acta 1023: 449-454, 1990.

35. Wieraszko A.
Evidence that ruthenium red disturbs the synaptic transmission in the rat hippocampal slices through interacting with sialic acid residues
Brain Res. 378: 120-126, 1986.

36. Groskreutz JL., Bronk SF., Gores GJ.
Ruthenium red delays the onset of cell death during oxidative stress of rat hepatocytes.
Gastroenterology. 102: 1030-1038, 1992.

37. Dessi F., Ben-Ari Y., Charriaut-Marlangue C.
Ruthenium red protects against glutamate- induced neuronal death in cerebellar culture
Neuroscience Letters. 201: 53-56, 1995.

38. Gomis A., Gutierrez LM., Sala F., Viniegra S., Reig JA.
Ruthenium red inhibits selectively chromaffin cell calcium channels
Biochem Pharmacol. 47: 2: 225-231, 1994.

39. Adams DJ., Takeda K., Umbach JA.
Inhibitors of calcium buffering depress evoked transmitter release at the squid giant synapse
J. Physiol. (Lond) 369: 145-159, 1985.

40. Baux G., Simonneau M., Tauc L.
Transmitter release: ruthenium red used to demonstrate a possible role of sialic acid containing substrates.
J. Physiol. (Lond) 291: 161-178, 1979.

41. Tapia R., Meza-Ruiz G.
Inhibition by ruthenium red of the calcium-dependent release of [3H]GABA in synaptosomal fractions.
Brain Res. 126: 160-166, 1977.

42. Lischka FW., Schild D.
Standing calcium gradients in olfactory receptor neurons can be abolished by amiloride or ruthenium red
J. Gen. Physiol. 102: 817-831, 1993.

43. Garcha RS., Hughes AD.
Action of heparin and ruthenium red on responses of reversibly-permeabilised rat mesenteric arteries
Eur. J. Pharmacol. Mol. Pharmacol. Sect. 268: 319-325, 1994.

44. Vites AM., Pappano AJ.
Ruthenium red selectively prevents ins(1,4,5)P3 but not caffeine-gated calcium release in avian atrium.
Am. J. Physiol. 262: H268, 1992.

45. Anghileri LJ. J. Nucl. Biol. Med. 18: 155-, 1974.

46. Ando A., Ando I., Hiraki T., Hisada K.
Distribution of 103Ru-Chloride in tumor-bearing animals and the mechanism for accumulation in tumor and liver.
Nucl. Med. Biol. 15: 2: 133-140, 1988.

47. Som P., Oster ZH., Matsui K., Guglielmi G., Persson BRR., Pellettieri ML., Srivastava SC., Richards P., Atkins HL., Brill AB.
97Ru-transferrin uptake in tumor and abscess.
Eur. J. Nucl. Med. 8: 491-494, 1983.

48. Srivastava SC., Richards P., Meinken GE., Larson SM., Grunbaum Z.
Tumor uptake of radioruthenium compounds. In: Radiopharmaceuticals Structure-Activity Relationships.
Eds. Spencer RP. Grune & Stratton New York, 207-223, 1981.

49. Tanabe M., Yamamoto G.
Tissue distribution of 97Ru and 103Ru in subcutaneous tumor of rodents
Acta Med. Okayama. 29: 431-436, 1975.

50. Waters SL.
Potential medical applications of ruthenium isotopes.
Coordination Chemistry Reviews. 52: 171-182, 1983.

51. Srivastava SC., Mausner LF., Clarke MJ.
Radioruthenium-labeled compounds for diagnostic tumor imaging.
In: Progress in Clinical Biochemistry and Medicine, vol 10, Springer-Verlag, Berlin, 111-149, 1989.

52. Chan PKL., Skov KA., James BR., Farrell NP.
A new ruthenium radiosensitizer: RuCl2(DMSO)2(4-nitroimidazole)2.
Int. J. Radiat. Oncol. Biol. Phys. 12: 1059-1062, 1986a.

53. Farrell N.
Metal complexes as radiosensitizer.
In: Progress in Clinical Biochemistry and Medicine, Springer-Verlag, Berlin, vol 10, 90-109, 1989.

54. Chan PKL., Skov KA., James BR., Farrell NP.
Chromosome-damaging activity of a ruthenium radio-sensitizer, RuCl2(DMSO)2 (4-nitroimidazole)2, in chinese hamster ovary cells in vitro.
Chem.-Biol. Interactions, 59: 247-254, 1986b.

55. Skov KA., Farrell NP.
Radiosensitization by metal complexes of 4(5)-nitroimidazole
Int. J. Radiat. Biol. 57: 947-958, 1990.

56. Dale LD., Tocher JH., Dyson TM., Edwards DI., Tocher DA.
Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds. II. A metronidazole adduct of a ruthenium-arene compound
Anti-Cancer Drug Design. 7: 3-14, 1992.

57. Monti-Bragadin C., Ramani L., Samer L., Mestroni G., Zassinovich G.
Effects of cis-dichlorodiammineplatinum (II) and related transition metal complexes on Escherichia coli.
Antimicrob. Agents and Chemother. 7: 6: 825-827, 1975a.

58. Monti-Bragadin C., Tamaro M., Banfi E.
Mutagenic activity of platinum and ruthenium complexes.
Chem.-Biol. Interactions 11: 469-472, 1975b.

59. Durig JR., Danneman J., Behnke WD., Mercer EE.
The induction of filamentous growth in Escherichia coli by ruthenium and palladium complexes.

13: 287-294, 1976.

60. Yasbin RE., Matthews CR., Clarke MJ.
Mutagenic and toxic effects of ruthenium.
Chem.-Biol. Interactions 31: 355-365, 1980.

61. Witkin EM.
Ultraviolet mutagenesis and inducible repair in Escherichia coli.

Bacteriol. Rev. 40: 869-..., 1976.

62. Barton JK., Lolis E.
Chiral discrimination in the covalent binding of bis(phenanthroline)dichlororuthenium(II) to B-DNA.
J. Am. Chem. Soc. 107: 708-709, 1985.

63. Pyle AM., Rehmann JP., Meshoyrer R., Kumar CV., Turro NJ., Barton JK.
Mixed-ligand complexes of ruthenium(II): factors governing binding to DNA.
J. Am. Chem. Soc. 111: 3051-3958, 1989.

64. Kelly JM., Feeney MM., Tossi AB., Lecomte J-P-. Kirsch-De Mesmaeker A.
Interaction of tetra-azaphenanthrene ruthenium complexes with DNA and oligonucleotides. A photophysical and photochemical investigation.

Anti-cancer Drug Design 5: 69-75, 1990.

65. Loseto F., Alessio E., Mestroni G., Lacidogna G., Nassi A., Giordano D., Coluccia M.
Interaction of RuCl2(dimethylsulphoxide)4 isomers with DNA.

Anticancer Res. 11: 1549-1554, 1991.

66. Novakova O., Kasparova J., Vrana O., van Vliet PM., Reedijk J., Brabec V.
Correlation between cytotoxicity and DNA binding of polypyridyl rutheniumcomplexes.
Biochemistry 34: 12369-12378, 1995.

67. Frühauf S., Zeller WJ.
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumour cells.
Cancer Res. 51: 2943-2948, 1991.

68. Bertolesi GE., Trigoso CI., Espada J., Stockert JC.
Cytochemical application of tris (2,2’-bipyridine) ruthenium(II): fluorescence reaction with sulfated polyanions of mast cell granules.

J. Histochem. Cytochem. 43: 5: 537-543, 1995.

69. Skotty DR., Nieman TA.
Determination of oxalate in urine and plasma using reversed-phase ion-pair high-performance liquid chromatography with tris(2,2’-bipyridyl)ruthenium(II)-electrogenerated chemiluminescence detection.

J. Chromatography B 665: 27-36, 1995.

70. Sasso MG., Quina FH., Bechara EJH.
Ruthenium(II) tris(bipyridyl) ion as a luminescent probe for oxygen uptake.

Anal. Biochem. 156: 239-243, 1986.

71. Terpetschnig E., Szmacinski H., Lakowicz JR.
Fluorescence polarization immunoassay of a high-molecular-weight antigen based on a long-lifetime Ru-ligand complex
Anal. Biochem. 227: 140-147, 1995.

72. Anghileri LJ.
The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calcium in the tumor.

Z. Krebsforsch. 83: 213-217, 1975.

73. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y.
Growth inhibition of Lewis lung carcinoma by an inorganic dye, ruthenium red.

Gann, 71: 151-154, 1980.

74. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y.
Prevention of vinblastine-induced cytotoxicity by ruthenium red.
Biochem. Pharmacol. 30: 213-216, 1981.

75. Conter V., Beck WT.
Impairment by ruthenium red of anticancer drug cytotoxicity in CCRF-CEM cells.

Biochem. Pharmacol. 32: 723-726, 1983.

76. Wilberding C., Kessel D.
Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells.
Biochem. Pharmacol. 33: 2559-2562, 1984.

77. Clarke MJ.,
Oncological implications of the chemistry of ruthenium. In: Metal Ions in Biological Systems
(Siegel H. Ed.), Marcel Dekker Inc., New York, pp 231-283, 1980.

78. Margalit R., Gray HB., Clarke MJ., Podbielski L.
Chemical and biological properties of pentaamineruthenium-bleomycin complex.
Chem. Biol. Interactions, 59: 231-245, 1986.

79. Keppler BK., Rupp W.
Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III). A representative of a new class of inorganic antitumor agents.

J. Cancer Res. Clin. Oncol. 111: 166-168, 1986.

80. Keppler BK., Balzer W., Seifried V.
Synthesis and antitumor activity of triazolium-bis-(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepenta-chlororuthenate (III). Two representatives of a new class of inorganic antitumor agents.

Arzneimittel-Forschung/Drug Res. 37: 770-771, 1987a.

81. Keppler BK., Wehe D., Endres H., Rupp W.
Synthesis, antitumor activity, and X-ray structure of bis(imidazolium)(imidazole)pentachlororuthenate(III), (ImH)2(RuImCl5).
Inorg. Chem. 26: 844-846, 1987b.

82. Keppler BK., Rupp W., Juhl UM., Endes H., Niebl R., Balzer W.
Synthesis, molecular structure, and tumor-inhibiting properties of imidazolium trans-bis(imidazole)tetrachlororuthenate(III) and its methyl-substituted derivatives.
Inorg. Chem. 26: 4366-4370, 1987c.

83. Garzon FT., Berger MR., Keppler BK., Schmähl D.
Comparative antitumor activity of ruthenium derivatives with 5’-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats.

Cancer Chemother. Pharmacol. 19: 347-349, 1987.

84. Berger MR., Garzon FT., Keppler BK., Schmähl D.
Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats.
Anticancer Res. 9: 761-766, 1989.

85. Seelig MH., Berger MR., Keppler BK.
Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats.

J. Cancer Res. Clin. Oncol. 118: 195-200, 1992.

86. Frühauf S., Zeller WJ.
In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors

Cancer Chemother. Pharmacol. 27: 301-307, 1991.

87. Sava G, Zorzet S, Perissin L, Mestroni G, Zassinovich G, Bontempi A.
Coordination metal complexes of Rh(I), Ir(I) and Ru(II): recent advances on antimetastatic activity on solid mouse tumors.
"Inorganica Chimica Acta", 137: 69-71 (1987).

88. Alessio E, Attia W, Calligaris M, Cauci S, Dolzani L, Mestroni G, MontiBragadin C, Nardin G, Quadrifoglio F, Sava G, Tamaro M, Zorzet S.
Metal complexes of platinum group: the promising antitumor features of cis-dichlorotetrakis-(dimethylsulfoxide) Ru(II) cis-RuCl2(Me2SO4) and related complexes.
In: "Platinum and other metal coordination compounds in cancer chemotherapy" (Marino Nicolini Ed.), pp. 617-633, Martinus Nijhoff Publishing, Boston, (1988a).

89. Alessio E, Mestroni G, Nardin G, Attia WM, Calligaris M, Sava G, Zorzet S.
Cis- and trans-Dihalotetrakis(dimethylsulfoxide)ruthenium(II) Complexes (RuX2(DMSO)4; X=Cl, Br): synthesis, structure and antitumor activity.
"Inorg Chem", 27: 4099-4106 (1988b).

90. Sava G, Pacor S, Ceschia V, Alessio E, Mestroni G.
Trans-Ru(II)dimethylsulphoxides: antineoplastic action on mouse tumors.
"Pharmacol Res", 21: 453-454 (1989a).

91. Sava G, Pacor S, Zorzet S, Alessio E, Mestroni G.
Antitumour properties of dimethylsulphoxide ruthenium(II) complexes in the Lewis lung carcinoma system.
"Pharmacol Res", 21: 617-628 (1989b).

92. Mestroni G, Alessio E, Calligaris M, Attia WM, Quadrifoglio F, Cauci S, Sava G, Zorzet S, Pacor S, Monti-Bragadin C, Tamaro M, Dolzani L.
Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide.
In: "Progress in Clinical Biochemistry and Medicine", pp. 71-87, Springer-Verlag, Berlin, (1989).

93. Pacor S, Luxich E, Ceschia V, Sava G, Alessio E, Mestroni G.
Effects of trans-RuCl2(DMSO)4 on B16 melanoma in mice.>.
"Pharmacol Res", 21 suppl 1: 127-128 (1989).

94. Sava G, Pacor S, Bregant F, Ceschia V, Luxich E, Alessio E, Mestroni G.
Mechanism of tumor inhibition by the metal complex trans-RuCl2(dimethylsulphoxide)4.
"Pharmacol (Life Sci Adv)", 9: 79-84 (1990a).

95. Sava G, Pacor S, Bregant F, Ceschia V.
Metal complexes of ruthenium: a potential class of selective anticancer drugs.
"Anticancer Res." 11: 1103-1108 (1991).

96. Pacor S, Sava G, Bregant F, Ceschia V, Alessio E, Mestroni G.
Antitumor action of mer-trichlorobis(dimethylsulphoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma.
In: "Metal Ions in Biology and Medicine" (Ph Collery, LA Poirier, M Manfait, JC Etienne, Eds), pp. 482-484, John Libbey Eurotext, Paris, (1990).

97. Pacor S, Sava G, Ceschia V, Bregant F, Mestroni G, Alessio E.
Antineoplastic effects of mer-trichlorobisdimethylsulphoxideaminorutheniumIII against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4].
"Chem.-Biol. Interactions" 78: 223-234 (1991).

98. Sava G, Pacor S, Mestroni G, Alessio E.
Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]° and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
"Anti-cancer Drugs" 3: 25-31 (1992a).

99. Pacor S, Sava G, Mestroni G, Alessio E.
Tumor inhibition and effects on host survival time by RutheniumIII and RhodiumIII complexes with dimethylsulphoxide ligands.

"Pharmacol. Res." 25, suppl. 1: 73-74 (1992).

100. Sava G, Pacor S, Mestroni G, Alessio E.
Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.

"Clin. Exp. Metastasis", 10: 273-280 (1992b).

101. Zeller WJ., Frü hauf S., Chen G., Keppler BK., Frei E., Kaufmann M.
Chemoresistance in rat ovarian tumours.
Eur. J. Cancer 27: 62-67, 1991.

102. Coluccia M, Sava G, Loseto F, Nassi A, Boccarelli A, Giordano D, Alessio E, Mestroni G.
Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388/DDP subline.

"Eur. J. Cancer", 29A: 1873-1879, 1993.

103. Gagliardi R, Sava G, Pacor S, Mestroni G, Alessio E.
Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.

"Clin. Exp. Metastasis", 12: 93-100, 1994.

104. Sava G, Pacor S, Coluccia M, Mariggiò M, Cocchietto M, Alessio E, Mestroni G.
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex.
"Drug Invest.", 8: 150-161, 1994.

105. Hellmann

106. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G, Alessio E.
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition.
"Chem.-Biol. Interct.", 95: 109-126, 1995.

107. Coluccia M, Sava G, Salerno G, Bergamo A, Pacor S, Mestroni G, Alessio E.
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)Im], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma.
"Metal Based Drugs", 2: 195-199, 1995.

108. Sava G, Zorzet S, Pacor S, Mestroni G, Zassinovich G.
Effects of two pyridinal-alkyliminerhodium(I) complexes in mice bearing MCa mammary carcinoma

"Cancer Chemother Pharmacol", 24: 302-306 (1989).

109. Kreuser ED., Keppler BK., Berdel WE., Piest A., Thiel E.
Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines.

Semin. Oncol. 19 suppl 2: 73-81, 1992.

110. Sava G, Salerno G, Bergamo A, Cocchietto M, Gaglierdi R, Alessio E, Mestroni G.
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization.
"Metal Based Drugs", 3: 67-73, 1996a.

111. Bergamo A., Cocchietto M., Capozzi I., Mestroni G., Alessio E., Sava G.
Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im] and ruthenium uptake by tumour cells.
Anti-Cancer Drugs, 7: 697-702, 1996.

112. Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S.
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex.
"Int.J. Cancer", 68: 60-66, 1996b.

Updating of published results

Plain language articles